AIM:BMK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge for the development of food and farming industries worldwide. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Benchmark Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BMK has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

BMK

1.1%

GB Pharmaceuticals

1.2%

GB Market


1 Year Return

-6.3%

BMK

7.9%

GB Pharmaceuticals

-13.2%

GB Market

Return vs Industry: BMK underperformed the UK Pharmaceuticals industry which returned 7.9% over the past year.

Return vs Market: BMK exceeded the UK Market which returned -13.2% over the past year.


Shareholder returns

BMKIndustryMarket
7 Day0%1.1%1.2%
30 Day9.8%0.2%-0.2%
90 Day13.9%-1.9%-1.1%
1 Year-6.3%-6.3%11.8%7.9%-9.8%-13.2%
3 Year12.5%12.5%54.4%37.0%-3.4%-15.1%
5 Year-53.8%-53.8%90.4%53.9%25.3%-2.7%

Price Volatility Vs. Market

How volatile is Benchmark Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Benchmark Holdings undervalued compared to its fair value and its price relative to the market?

0.97x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BMK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BMK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BMK is unprofitable, so we can't compare its PE Ratio to the GB Pharmaceuticals industry average.

PE vs Market: BMK is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BMK is good value based on its PB Ratio (1x) compared to the GB Pharmaceuticals industry average (4.3x).


Next Steps

Future Growth

How is Benchmark Holdings forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

54.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BMK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BMK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BMK's revenue (14% per year) is forecast to grow faster than the UK market (6.2% per year).

High Growth Revenue: BMK's revenue (14% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BMK's Return on Equity is forecast to be low in 3 years time (0%).


Next Steps

Past Performance

How has Benchmark Holdings performed over the past 5 years?

-48.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BMK is currently unprofitable.

Growing Profit Margin: BMK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BMK is unprofitable, and losses have increased over the past 5 years at a rate of 48.4% per year.

Accelerating Growth: Unable to compare BMK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.8%).


Return on Equity

High ROE: BMK has a negative Return on Equity (-25.86%), as it is currently unprofitable.


Next Steps

Financial Health

How is Benchmark Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: BMK's short term assets (£139.6M) exceed its short term liabilities (£50.0M).

Long Term Liabilities: BMK's short term assets (£139.6M) do not cover its long term liabilities (£141.3M).


Debt to Equity History and Analysis

Debt Level: BMK's debt to equity ratio (31.6%) is considered satisfactory.

Reducing Debt: BMK's debt to equity ratio has increased from 0.07% to 31.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BMK has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BMK has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 11% each year


Next Steps

Dividend

What is Benchmark Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: BMK is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BMK's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Trond Williksen (57 yo)

0.25

Tenure

Mr. Trond Williksen serves as Chief Executive Officer and Director at Benchmark Holdings plc since June 01, 2020. He serves as the Executive Advisor at FSN Capital Partners AS since July 2019. Prior to thi ...


Leadership Team

NamePositionTenureCompensationOwnership
Trond Williksen
CEO & Director0.25yrno data0.027%
£ 81.0k
Ruth Layton
Co-Founder & Head of Benchmark Sustainability Scienceno dataUK£14.18kno data
Septima Maguire
CFO & Director0.75yrno data0.040%
£ 119.2k
Ivonne Cantu
Director of Investor Relations & Corporate Developmentno datano datano data
Jennifer Haddouk
Company Secretary & Group Legal Counsel1.33yrsno datano data
Doerte Laue
Group Marketing Director1.92yrsno datano data
Anna Winton
Head of Peopleno datano datano data
Roland Bonney
Group Lead of Key Account Management2.67yrsUK£271.00kno data
Athene Blakeman
Head of Advanced Nutritionno datano datano data
David Babington
Managing Director of Improve Internationalno datano datano data
James Banfield
Head of Knowledge Services2.67yrsno datano data
John Marshall
Head of Animal Health2.67yrsno datano data

1.9yrs

Average Tenure

Experienced Management: BMK's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Trond Williksen
CEO & Director0.25yrno data0.027%
£ 81.0k
Septima Maguire
CFO & Director0.75yrno data0.040%
£ 119.2k
Kevin Quinn
Independent Non-Executive Director3.83yrsUK£45.00k0.013%
£ 38.7k
Yngve Myhre
Independent Non-Executive Director2.83yrsUK£45.00k0.12%
£ 360.0k
Kristian Eikre
Non-Executive Director1.5yrsno datano data
Susan Jane Searle
Senior Independent Non-Executive Directorno dataUK£45.00k0.030%
£ 89.1k
Peter George
Non-Executive Chairman2.33yrsUK£120.00k0.45%
£ 1.4m
Hugo Wahnish
Independent Non-Executive Director2.83yrsUK£45.00k0.052%
£ 157.5k

2.3yrs

Average Tenure

57yo

Average Age

Experienced Board: BMK's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BMK insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.6%.


Top Shareholders

Company Information

Benchmark Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Benchmark Holdings plc
  • Ticker: BMK
  • Exchange: AIM
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£300.448m
  • Shares outstanding: 667.66m
  • Website: https://www.benchmarkplc.com

Number of Employees


Location

  • Benchmark Holdings plc
  • Benchmark House
  • 8 Smithy Wood Drive
  • Sheffield
  • South Yorkshire
  • S35 1QN
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMKAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2013
BHCC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2013
31BDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2013

Biography

Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge for the development of food and farming industries worldwide. The company operates th ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 03:27
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.